Cancer Research 09 AM Call for Abstracts  SU2C
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pitha-Rowe, I.
Right arrow Articles by Dmitrovsky, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pitha-Rowe, I.
Right arrow Articles by Dmitrovsky, E.
[Cancer Research 64, 8109-8115, November 1, 2004]
© 2004 American Association for Cancer Research


Epidemiology and Prevention

Microarray Analyses Uncover UBE1L as a Candidate Target Gene for Lung Cancer Chemoprevention

Ian Pitha-Rowe1, W. Jeffrey Petty2, Qing Feng1, Petra H. Koza-Taylor5, Debra A. DiMattia5, Lynn Pinder5, Konstantin H. Dragnev2,4, Natalie Memoli3, Vincent Memoli3,4, Tom Turi5, Jean Beebe5, Sutisak Kitareewan1 and Ethan Dmitrovsky1,2,4

1 Departments of Pharmacology and Toxicology, 2 Medicine, 3 Pathology, and 4 the Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, New Hampshire; Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; and 5 Pfizer Global Research and Development, Groton, Connecticut

Retinoids, natural and synthetic derivatives of vitamin A, are active in cancer therapy and chemoprevention. We reported previously that all-trans-retinoic acid (RA) treatment prevented carcinogen-induced transformation of immortalized human bronchial epithelial (HBE) cells. To identify cancer chemopreventive mechanisms, immortalized (BEAS-2B), carcinogen-transformed (BEAS-2BNNK), and RA-chemoprevented (BEAS-2BNNK/RA) HBE cells were used to conduct microarray analyses independently. Species increased in chemoprevented as compared with immortalized HBE cells (group I) and those augmented in chemoprevented as compared with transformed HBE cells (group II) included known RA-target genes as well as previously unrecognized RA-target genes in HBE cells. Unexpectedly, both groups were also enriched for interferon-stimulated genes. One interferon-stimulated gene of particular interest was UBE1L, the ubiquitin-activating enzyme E1-like protein. UBE1L expression was also induced after prolonged RA-treatment of immortalized HBE cells. UBE1L mRNA was shown previously as repressed in certain lung cancer cell lines, directly implicating UBE1L in lung carcinogenesis. Notably, UBE1L immunoblot expression was reduced in a subset of malignant as compared with adjacent normal lung tissues that were examined. Immunohistochemical analyses were performed using a new assay developed to detect this species using rabbit polyclonal anti-UBE1L antibodies independently raised against the amino- or carboxyl-termini of UBE1L. Studies done on paraffin-embedded and fixed tissues revealed abundant UBE1L, but low levels of cyclin D1 expression in the normal human bronchial epithelium, indicating an inverse relationship existed between these species. To study this further, cotransfection into HBE cells of wild-type or mutant UBE1L species was accomplished. In a dose-dependent manner, wild-type but not mutant UBE1L species repressed cyclin D1 expression. This implicated UBE1L in a retinoid chemoprevention mechanism involving cyclin D1 repression described previously. Taken together, these findings directly implicate UBE1L as a candidate-pharmacologic target for lung cancer chemoprevention. These findings also provide a mechanistic basis for the tumor suppressive effects of UBE1L through cyclin D1 repression.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
S. J. Shah, S. Blumen, I. Pitha-Rowe, S. Kitareewan, S. J. Freemantle, Q. Feng, and E. Dmitrovsky
UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation
Mol. Cancer Ther., April 1, 2008; 7(4): 905 - 914.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. J. Reu, S. I. Bae, L. Cherkassky, D. W. Leaman, D. Lindner, N. Beaulieu, A. R. MacLeod, and E. C. Borden
Overcoming Resistance to Interferon-Induced Apoptosis of Renal Carcinoma and Melanoma Cells by DNA Demethylation
J. Clin. Oncol., August 10, 2006; 24(23): 3771 - 3779.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
S. J. Freemantle, K. H. Dragnev, and E. Dmitrovsky
The retinoic Acid paradox in cancer chemoprevention.
J Natl Cancer Inst, April 5, 2006; 98(7): 426 - 427.
[Full Text] [PDF]


Home page
aacredbookHome page
E. Dmitrovsky
D-Type Cyclins as Novel Targets for Chemoprevention
Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 59 - 63.
[Full Text] [PDF]


Home page
JCOHome page
F. R. Hirsch and S. M. Lippman
Advances in the Biology of Lung Cancer Chemoprevention
J. Clin. Oncol., May 10, 2005; 23(14): 3186 - 3197.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.